Indication

For the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features

Medicine details

Medicine name:
ofatumumab (Kesimpta)
SMC ID:
SMC2357
Pharmaceutical company
Novartis Pharmaceuticals UK Ltd
BNF chapter
Central nervous system
Submission type
Full
Publication due date:
12 July 2021
Patient group submission deadline:
03 May 2021